Novel UHPLC-MS/MS method for the determination of rotigotine in the plasma of patients with Parkinson's disease

被引:7
作者
Mohamed, Susan [1 ]
Riva, Roberto [1 ,2 ]
Contin, Manuela [1 ,2 ]
机构
[1] IRCCS ISNB Inst Neurol Sci Bologna, Bologna, Italy
[2] Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy
关键词
dopamine receptor agonist; Parkinson's disease; rotigotine; UHPLC-MS/MS; TRANSDERMAL ROTIGOTINE; PATCH;
D O I
10.1002/bmc.3944
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A novel ultra-high-pressure liquid chromatography-tandem mass spectrometry method was developed and validated for the determination of the dopamine receptor agonist rotigotine in human plasma. Following liquid-liquid extraction with tert-butyl methyl ether from 500 mu L plasma, the chromatographic analysis was performed on a Gemini NX3 column using 5mm pH 5.0 ammonium acetate-5mm ammonium acetate in methanol as binary gradient mobile phase, at a flow rate of 0.3 mL/min. The MS/MS ion transitions were 316.00 -> 147.00 for rotigotine and 256.10 -> 211.00 for the internal standard (lamotrigine). The lower limit of quantitation was 50 pg/mL and the linearity was determined from 50 to 2500 pg/mL. The mean recovery was 96.9%. Both intra-and interassay imprecision and inaccuracy were 15% at all quality control concentrations. The method was successfully applied to measure morning trough plasma rotigotine concentrations in a series of patients with Parkinson's disease on chronic treatment. The present study describes the first fully validated method for rotigotine determination in human plasma.
引用
收藏
页数:6
相关论文
共 13 条
  • [1] Braun M., 2005, EUR FED NEUR SCI ATH
  • [2] Transdermal administration of radiolabelled [14C]rotigotine by a patch formulation -: A mass balance trial
    Cawello, Willi
    Wolff, Hans Michael
    Meuling, Wim J. A.
    Horstmann, Rolf
    Braun, Marina
    [J]. CLINICAL PHARMACOKINETICS, 2007, 46 (10) : 851 - 857
  • [3] Single dose pharmacokinetics of the transdermal rotigotine patch in patients with impaired renal function
    Cawello, Willi
    Ahrweiler, Sascha
    Sulowicz, Wladyslaw
    Szymczakiewicz-Multanowska, Agnieszka
    Braun, Marina
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 73 (01) : 46 - 54
  • [4] Absorption, Disposition, Metabolic Fate, and Elimination of the Dopamine Agonist Rotigotine in Man: Administration by Intravenous Infusion or Transdermal Delivery
    Cawello, Willi
    Braun, Marina
    Boekens, Hilmar
    [J]. DRUG METABOLISM AND DISPOSITION, 2009, 37 (10) : 2055 - 2060
  • [5] Levodopa therapy monitoring in patients with Parkinson disease: a kinetic-dynamic approach
    Contin, M
    Riva, R
    Martinelli, P
    Albani, F
    Avoni, P
    Baruzzi, A
    [J]. THERAPEUTIC DRUG MONITORING, 2001, 23 (06) : 621 - 629
  • [6] An Update on Pharmacological, Pharmacokinetic Properties and Drug-Drug Interactions of Rotigotine Transdermal System in Parkinson's Disease and Restless Legs Syndrome
    Elshoff, Jan-Peer
    Cawello, Willi
    Andreas, Jens-Otto
    Mathy, Francois-Xavier
    Braun, Marina
    [J]. DRUGS, 2015, 75 (05) : 487 - 501
  • [7] Steady-State Plasma Concentration Profile of Transdermal Rotigotine: An Integrated Analysis of Three, Open-Label, Randomized, Phase I Multiple Dose Studies
    Elshoff, Jan-Peer
    Braun, Marina
    Andreas, Jens-Otto
    Middle, Michelle
    Cawello, Willi
    [J]. CLINICAL THERAPEUTICS, 2012, 34 (04) : 966 - 978
  • [8] EMEA (European Medicines Agency), 2011, EMEA/CHMP/EWP/192217/2009
  • [9] ICH, 1996, 3 INT C HARM TECHN R
  • [10] Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS
    Matuszewski, BK
    Constanzer, ML
    Chavez-Eng, CM
    [J]. ANALYTICAL CHEMISTRY, 2003, 75 (13) : 3019 - 3030